After dramatic rebuke, AstraZeneca lowers vaccine efficacy estimate—a bit of

A vial of the AstraZeneca/Oxford vaccine is pictured at a coronavirus vaccination center at the Wanda Metropolitano stadium in Madrid on March 24, 2021.

Enlarge / A vial of the AstraZeneca/Oxford vaccine is pictured at a coronavirus vaccination middle on the Wanda Metropolitano stadium in Madrid on March 24, 2021. (credit score: Getty | Gabriel Bouys)

Brushing apart a dramatic rebuke from authorities researchers and unbiased specialists, AstraZeneca on Wednesday evening introduced {that a} new evaluation discovered its COVID-19 vaccine to be 76 p.c efficient at stopping symptomatic COVID-19—down from the 79 p.c efficacy estimate it introduced in a press launch Monday.

The brand new estimate remains to be excessive, in response to an unbiased board of specialists tasked with overseeing the vaccine’s trial and information evaluation. The trial’s Information and Security Monitoring Board (DSMB) despatched a extremely uncommon letter to AstraZeneca quickly after the Monday press launch, noting that trial information it had seen throughout February and March conferences urged that the vaccine’s efficacy was really between 69 p.c and 74 p.c.

“The DSMB is worried that AstraZeneca selected to make use of information that was already outdated and doubtlessly deceptive of their press launch,” the letter acknowledged. “The purpose that’s clear to the board is that the [vaccine efficacy number]… they selected to launch was essentially the most favorable for the examine versus the newest and most full. Choices like this are what erode public belief within the scientific course of.”

Learn eight remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.